Release No 9/2010 Affitech Increases Share Capital - Share capital increased to DKK 243,860,769.50 through an issue of 260,187,010 new shares each of nominal value DKK 0.50 - The subscription price of DKK 0.60 values the total subscription at DKK 156,112,206.00 - The subscription of new shares is without pre-emption rights for the existing shareholders and all new shares will be taken up by Trans Nova Investments Limited, Cyprus - Trans Nova enters a standstill agreement not to increase shareholding for next 12 months Copenhagen and Oslo, April 21, 2010 Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced an increase in share capital as part of the equity investment in Affitech by Trans Nova Investments Limited. Increase in Share Capital of the Company Based on the authorisation provided in article 4 of the Company's Articles of Association, the Board of Directors has decided to issue 260,187,010 new shares, each of nominal value DKK 0,50 and, thus, to increase the share capital of the company to DKK 243,860,769.50. The subscription will be exercised at a subscription price of DKK 0.60 for each share and the total subscription price will be DKK 156,112,206.00. The subscription of the new shares is without pre-emption rights for the existing shareholders and all new shares will be subscribed for by Trans Nova Investments Limited, Cyprus. The subscription price will be paid on or before 27 April 2010 following which the share capital increase will be registered with the Danish Commerce and Companies Agency. Trans Nova has agreed not to purchase further shares in Affitech for the next 12 months, subject to Trans Nova being granted a dispensation from the obligation to make a mandatory takeover offer to the other shareholders in Affitech by the Danish Financial Supervisory Authority. -------------------------------------------------------------------------------- | For more information please contact: | -------------------------------------------------------------------------------- | | | Affitech A/S: | | | | Dr Robert Burns, Chief Executive Officer, | | Tel # +45 50 99 76 42 | | Randi Krogsgaard, Corporate Communications | | Tel # +45 23 10 10 01 | | Randi@affitech.com | -------------------------------------------------------------------------------- About Affitech Affitech AS is a publicly traded (NASDAQ OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitechs premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.